Posts Tagged ‘healthcare’

TGE shouts, CSCO sells widely, XNPT dips

Monday, March 21st, 2011

TGC Industries Inc. (Nasdaq: TGE) shares soared 14.5% to $7.82, on volume of 603,000 shares, or eight times its daily volume, after Dawson Geophysical Co. (Nasdaq: DWSN) said it would acquire the provider of seismic data to oil and gas producers for about $157 million in stock. DWSN shares advanced 1.1% to $43.00.

Cisco Systems (Nasdaq: CSCO) dealt in 24.7 million shares, catching up rapidly on a daily average of 71.2 million. Share prices gained 1.9% to $17.47.

XenoPort Inc.(Nasdaq: XNPT) shares fell 10.3% to $5.98, on volume of 4.4 million, or nine times its daily volume, after the company said it would halt development of its experimental heartburn treatment.

ARSC jumps, ELCR fires on all cylinders, GNTA falls

Monday, March 21st, 2011

American Security Resources Corp. (OTCBB: ARSC) flew out of the blocks Monday, doubling in price to two-100ths of a cent, on volume of 125 million shares, outdistancing its daily average of 72 million.

Electric Car Company Inc. (OTCBB: ELCR) revved up a lot of investors Monday, trading in 22 million, still quite a ways from its daily volume of 126.4 million. The stock’s price was flat, at however, at one-100th of a cent. The Missouri-based ELCR is a vehicle conversion company that specializes in electric conversions and manufacturing for the livery, fleet and private specialty markets.

Genta Inc. (OTCBB: GNTA) slumped in price 86.8% to 4.3 cents. Volume was 3.5 million shares, nearly quadruple its daily average. The New Jersey-based GNTA is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer.

CRIS soars, C active, S slips

Monday, March 21st, 2011

Curis Inc. (Nasdaq: CRIS) shares climbed 14% to $3.34, on three million shares, or five times its daily average, after the drug developer and its partner Roche Group announced positive results from a midstage study of their skin-cancer treatment.

Citigroup Inc. (NYSE: C) traded in 263 million shares Monday, closing in on a daily average of 482 million. C announced Monday it will slash the number of common shares outstanding through a 1-for-10 reverse stock split, and reintroduce a dividend

Sprint Nextel Corp. (NYSE: S) shares declined 13.4% to $4.38, on volume of 134 million shares, better than double its daily average of 55 million, a trading day after rival AT&T Inc. (NYSE: T) said it would acquire T-Mobile USA from Deutsche Telekom AG in a $39-billion deal that would make AT&T the largest U.S. wireless carrier.

BKD grows, S rings it up, ALAN slumps

Thursday, February 24th, 2011

Brookdale Senior Living Inc. (NYSE: BKD) shares gained 9% to $25.55, on share volume of 1.8 million, or twice its average, a day after the operator of assisted-living housing reported a narrower fourth-quarter loss. Earlier Thursday, the company announced an agreement for an expanded corporate line of credit.

Sprint Nextel Corp. (Nasdaq: S) traded Thursday in 56.8 million shares, surpassing its daily average of 52.3 million. Prices added 1.8% to $4.28, after taking the wraps off its HTC Arrive smart phone.

Alanco Technologies Inc. (Nasdaq: ALAN) subsided 13.3% to $1.04 Thursday, on share volume of 113,000, more than six times its daily average.

PCLN beams up, CSCO deals, SLXP sliced and diced

Thursday, February 24th, 2011

Priceline.com Inc. (Nasdaq: PCLN) shares were up 7.1% to $456.11, on share volume of 2.9 million shares, or three times its average, a day after the online travel-booking service said its fourth-quarter net income rose 73%.

Cisco Systems Inc. (Nasdaq: CSCO) was among volume leaders Thursday, particularly among tech stocks, by trading in 30.6 million shares, nearly half its all-day average of 71.9 million. Prices for CSCO were flat at $18.39

Salix Pharmaceuticals Inc. (Nasdaq: SLXP) stumbled in price to 22.8% to $32.01 Thursday, on share volume of 8.9 million, more than 10 times its daily average, after the Raleigh company said that the FDA wasn’t ready to approve one of its drug candidates without more information.